It is with great pleasure that we introduce the Enterovirus Foundation!
The Enterovirus Foundation, founded in November 2008, is a non-profit organization created to fund research to discover the persistent effects of enteroviruses, to determine the role they play in both acute and chronic disease, and to develop treatments to cure and prevent these diseases.
Even though the Enterovirus Foundation is just getting started, we have big plans for 2009. Here are our prospective projects.
Determine the role of EV in disease
The EV Foundation will provide pilot grants for promising scientific and clinical research. For inquiries about our grant process, contact info@EnterovirusFoundation.org
Find antiviral compounds for effective treatment
The EV Foundation will support studies for the development of antiviral and antienteroviral medications. Our preliminary plans are to work with organizations such as the Rega Institute in Belgium and the US Centers for Disease Control and Prevention to extend and accelerate work that is already in progress.
Develop better diagnostic capabilities for "hard to detect" enteroviral infections
After the acute phase of an infection, enteroviruses can leave the blood serum and cerebral spinal fluid, completely retreating to organs and other tissue. As a result, it can be difficult to diagnose enteroviral infections without a biopsy, and even then, the tests are limited. The EV Foundation will work with scientists and diagnostic companies to develop better diagnostic tools for detecting these viruses more quickly, less invasively, and with methods that work in less advantaged areas of the world.
Accelerate communication across the research and medical communities
The EV Foundation will sponsor an international conference every year to encourage collaboration between scientists and medical professionals for the purpose of sharing knowledge and determining the most effective use of research funding.
Raise public awareness and improve education about enterovirusesThe goal of this Website is to create a global "go to" web-exchange for scientists, clinicians, patients, and the general public. We look forward to your input in order to make this an informative and useful site for all of its readers, whether they are medical professionals, scientists, or patients who are sick and looking for answers.
Board of Directors
Nora Chapman, PhDis a Research Scientist at the University of Nebraska Enterovirus Research Laboratory and Associate Professor at the University of Nebraska. Dr. Chapman studies persistent coxsackie infections in murine models of chronic myoccarditas and dilated cardiomyopathy. She and her associates have demonstrated that selection of defective enterovirus in heart and other tissues leads to persistent infections despite active antiviral immune responses. Dr. Chapman is presently studying the mode of selection of these viruses and the effects of replication of these viruses upon infected cell function. Dr. Chapman and her associates at the University of Nebraska are further investigating Dr. John Chia's work in regards to enterovirus in the gut biopsies.
John Chia, MD, is the President of EV Med Research, Owner/Physician at Infectious Disease Med, and Assistant Professor at the UCLA School of Medicine. Dr. Chia is an infectious disease specialist and studies the role of enteroviral infections in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) Dr. Chia recently published original research from a study that found 135 out of 165 (82%) of CFS/ME patients had stomach biopsy samples that stain positive for enteroviral antigens compared with 7 out of 34 (20%) of the controls. He also found that 9 out of 24 (37%) of CFS/ME patients had enteroviral RNA in their gut tissues compared to 1 out of 21 controls. Currently, Dr. Chia is investigating treatment strategies for persistent enteroviral infections.
Andrew Chia, is an Associate at EV MED Research, LLC. Mr. Chia received his BS in Biological Science with Cum Laude in 2006 from the University of California at Irvine. Having recovered from chronic fatigue syndrome/myalgic encephalomyelitis, Mr. Chia is dedicated to researching the role of enteroviral infections in CFS/ME. Mr. Chia developed the immunoperoxidase staining procedure currently used in enteroviral research and is working with Dr. Chia to investigate treatment strategies for persistent enteroviral infections.
Daniel R. McClernon is the President of McClernon, LLC, a scientific consulting company that focuses on pharmaceutical, biomarker, and clinical diagnostic development within the infectious disease space. Mr. McClernon has 25 years experience in drug discovery, molecular diagnostics and business development. He began his scientific career at Burroughs Wellcome pharmaceutical company where he studied DNA Topoisomerse and Herpes Simplex Virus (HSV). He co-developed a DNA cleavable complex assay used to screen anti-cancer compounds, and also worked on characterizing HSV clinical isolates for acyclovir FDA submissions. In 1995 Mr. McClernon began working in HIV clinical research, thus contributing to the FDA approvals of HIV drugs Ziagen, Trizivir, Lexiva and Combivir. He also applied molecular technologies for clinical applications pursuant to drug resistance, viral load and NeuroAIDS research. In addition, Mr. McClernon has published extensively and has led collaborative projects with major medical centers as well as pharmaceutical and diagnostic companies.
Steven Tracy, PhD is a Professor in the Department of Pathology and Microbiology at the University of Nebraska Medical Center and organizer of the Enterovirus Research Laboratory for the study entero- and picornaviral biologies. Dr. Tracy has studied the molecular biology, pathogenesis, and immunology of the Group B coxsackieviruses for 25 years. Together with colleagues, he cloned and characterized the RNA genomes of these viruses, demonstrated their ability to express biologically active proteins and antigenic epitopes, verified approaches to attenuating these viruses for use as vaccine and/or expression vectors, and explored their etiologic involvement in inflammatory heart disease. In additional collaboration, he developed new models to study the involvement of these viruses in either preventing or inducting type 1 diabetes. Most recently he collaborated in the discovery of a novel and unsuspected mechanism by which human enteroviruses can persist for long periods of time in the immune host. Dr. Tracy has published numerous research and review articles about human enteroviruses and the group B coxsackieviruses. He co-edited a definitive volume of Current Topics in Microbiology and Immunology, Volume 323, titled "Group B Cocksackieviruses."
Lisa Ross Faust is the Co-Founder/Executive Director of the Enterovirus Foundation and the Co-Owner/Managing Partner for the Contemporary Events Group (CEG), LLC, a full service event, meeting and incentive company. CEG's partial client list includes medical diagnostics leaders such as bioMerieux and Gen-Probe, as well as Nike, Michael Jordan, Sony Playstation, The Weather Channel, Nokia Siemens Networks, TransUnion, and Siemens Communications. After Ms. Faust's personal experience with a persistent enteroviral infection that caused a systemic multi-organ illness and the subsequent infection of her daughter, she organized the Enterovirus Foundation dedicated to research, public awareness, and antiviral medications to help sufferers of both acute and chronic enteroviral disease.
Rachel Landphere is the Co-Founder/Director of the Enterovirus Foundation. Ms. Landphere is an experienced director with a background in administration, project management, fund raising, brand awareness and presence marketing that makes her uniquely qualified to drive the start-up of the Enterovirus Foundation. As a project manager, Ms. Landphere has handled all aspects of large corporate event projects, including celebrity participation for fundraising events, brand promotion programs, client education seminars, and corporate outings. In addition, she has led campaigns to raise awareness for a variety of non-profits including the Anheuser-Busch beneficiary, the National Hispanic Scholarship Fund, the Georgia Chapter of Juvenile Diabetes Foundation, the American Parkinson's Disease Association, and the Special Olympics.